LCP-Tacro meets Phase III endpoint

LifeCycle Pharma A/S (CSE:LCP) said once-daily LCP-Tacro met the primary endpoint of non-inferiority to twice-daily Prograf tacrolimus on a composite of death, graft failure, biopsy-proven acute rejection or loss to follow-up at 12 months as measured by local biopsy reading in the Phase III Study 3001 trial to prevent organ transplant rejection in stable renal transplant recipients (2.5% for both). The open-label, international trial enrolled 326 patients. ...